JP2025513289A - ファルネソイドｘ受容体アゴニストの使用 - Google Patents
ファルネソイドｘ受容体アゴニストの使用 Download PDFInfo
- Publication number
- JP2025513289A JP2025513289A JP2024561602A JP2024561602A JP2025513289A JP 2025513289 A JP2025513289 A JP 2025513289A JP 2024561602 A JP2024561602 A JP 2024561602A JP 2024561602 A JP2024561602 A JP 2024561602A JP 2025513289 A JP2025513289 A JP 2025513289A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- compound
- pharma
- score
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333287P | 2022-04-21 | 2022-04-21 | |
| US63/333,287 | 2022-04-21 | ||
| US202263381752P | 2022-10-31 | 2022-10-31 | |
| US63/381,752 | 2022-10-31 | ||
| PCT/US2023/019448 WO2023205447A2 (en) | 2022-04-21 | 2023-04-21 | Uses of farnesoid x receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513289A true JP2025513289A (ja) | 2025-04-24 |
| JP2025513289A5 JP2025513289A5 (https=) | 2026-04-28 |
Family
ID=88420596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024561602A Pending JP2025513289A (ja) | 2022-04-21 | 2023-04-21 | ファルネソイドｘ受容体アゴニストの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250288600A1 (https=) |
| EP (1) | EP4511012A2 (https=) |
| JP (1) | JP2025513289A (https=) |
| KR (1) | KR20250006156A (https=) |
| CN (1) | CN119136794A (https=) |
| AU (1) | AU2023257308A1 (https=) |
| CA (1) | CA3249500A1 (https=) |
| IL (1) | IL315941A (https=) |
| MX (1) | MX2024012966A (https=) |
| WO (1) | WO2023205447A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4611888A1 (en) * | 2022-10-31 | 2025-09-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017004708A2 (pt) * | 2014-09-12 | 2017-12-05 | Tobira Therapeutics Inc | terapia de combinação de cenicriviroc para o tratamento de fibrose |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| ES2874682T3 (es) * | 2016-03-11 | 2021-11-05 | Intercept Pharmaceuticals Inc | Derivados de 3-desoxi y composiciones farmacéuticas de los mismos |
| BR112019027458A2 (pt) * | 2017-06-23 | 2020-07-07 | Intercept Pharmaceuticals, Inc. | métodos e intermediários para a preparação de derivados de ácidos biliares |
-
2023
- 2023-04-21 WO PCT/US2023/019448 patent/WO2023205447A2/en not_active Ceased
- 2023-04-21 AU AU2023257308A patent/AU2023257308A1/en active Pending
- 2023-04-21 US US18/858,674 patent/US20250288600A1/en active Pending
- 2023-04-21 IL IL315941A patent/IL315941A/en unknown
- 2023-04-21 CA CA3249500A patent/CA3249500A1/en active Pending
- 2023-04-21 JP JP2024561602A patent/JP2025513289A/ja active Pending
- 2023-04-21 KR KR1020247038272A patent/KR20250006156A/ko active Pending
- 2023-04-21 EP EP23792602.7A patent/EP4511012A2/en active Pending
- 2023-04-21 CN CN202380035124.0A patent/CN119136794A/zh active Pending
-
2024
- 2024-10-21 MX MX2024012966A patent/MX2024012966A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023205447A3 (en) | 2024-04-04 |
| US20250288600A1 (en) | 2025-09-18 |
| CA3249500A1 (en) | 2023-10-26 |
| WO2023205447A2 (en) | 2023-10-26 |
| MX2024012966A (es) | 2024-11-08 |
| KR20250006156A (ko) | 2025-01-10 |
| EP4511012A2 (en) | 2025-02-26 |
| IL315941A (en) | 2024-11-01 |
| AU2023257308A1 (en) | 2024-10-10 |
| CN119136794A (zh) | 2024-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5094384B2 (ja) | Ｆｘｒリガンドを使用する線維症の処置 | |
| JP2021063088A (ja) | 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 | |
| Trauner et al. | Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC | |
| JP2020147585A (ja) | 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤 | |
| Talwalkar et al. | Mycophenolate mofetil for the treatment of primary sclerosing cholangitis | |
| Polyzos et al. | Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease | |
| CA3125341A1 (en) | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) | |
| WO2023078435A1 (zh) | 叶酸在预防、诊断和治疗遗传性、感染性或过敏性疾病中的应用 | |
| JP2025513289A (ja) | ファルネソイドｘ受容体アゴニストの使用 | |
| US20260097039A1 (en) | Methods for treating a fatty liver disease | |
| Díaz et al. | Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease | |
| Debiec et al. | Antenatal membranous glomerulonephritis with vascular injury induced by anti-neutral endopeptidase antibodies: toward new concepts in the pathogenesis of glomerular diseases | |
| WO2024097247A1 (en) | Uses of farnesoid x receptor agonists | |
| Matsuo | Fluorescein angiographic features of tubulointerstitial nephritis and uveitis syndrome | |
| US20230405078A1 (en) | Detection and treatment of intestinal fibrosis | |
| Pagán et al. | Budesonide combined with ursodeoxycholic acid in primary biliary cirrhosis with advanced liver damage | |
| CN115605198B (zh) | 脂肪性肝病的治疗药 | |
| Pluimakers | Late metabolic consequences of childhood cancer | |
| Planinsic et al. | Post reperfusion changes during small bowel transplantation | |
| HK40080642A (en) | Therapeutic agent for fatty liver disease | |
| Lithgow | C-reactive protein, an inflammation marker, in nipple aspirate fluid: Relation to breast cancer risk, body mass index, lipids and carotenoids | |
| Kóbori et al. | THE USE OF AUTOLOGOUS RECTUS FASCIA SHEATH FOR REPLACEMENT OF INFERIOR CAVAL VEIN DEFECTS IN ORTHOTOPIC LIVER TRANSPLANTATION | |
| Pirenne et al. | “PROPE” TOLERANCE AFTER INTESTINAL TRANSPLANTATION IN MAN. | |
| François et al. | Late-breaking abstracts | |
| Reidy et al. | PHYSICAL AND OCCUPATIONAL REHABILITATION BEFORE AND AFTER INTESTINAL TRANSPLANTATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260420 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260420 |